We are live on ! Find out more
PCRX icon

Pacira BioSciences
PCRX

Delisted

PCRX was delisted on the 16th of November, 2026.

258 hedge funds and large institutions have $1.15B invested in Pacira BioSciences in 2026 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 94 increasing their positions, 85 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

263% more call options, than puts

Call options by funds: $872K | Put options by funds: $240K

74% more capital inflows, than outflows

Capital inflows: $119M | Capital outflows: $68.4M

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

36% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 25

11% more repeat investments, than reductions

Existing positions increased: 94 | Existing positions reduced: 85

3.48% more ownership

Funds ownership: 111.68% → 115.16% (+3.5%)

2% more funds holding

Funds holding: 254 → 258 (+4)

Holders
258
Holders Change
+4
Holders Change %
+1.57%
% of All Funds
3.14%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
34
Increased
94
Reduced
85
Closed
25
Calls
$872​K
Puts
$240​K
Net Calls
+$632​K
Net Calls Change
+$31​K

PCRX Hedge Fund Activity: Q3 2026 in Review

258 of the 8,220 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q3 2026, worth a combined $1.15B — up 2.9% from $1.12B a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new PCRX positions and 25 closed out — a net gain of 9 holders — while 94 added to existing stakes and 85 trimmed.

The largest buyer was Jacobs Levy Equity Management, adding an estimated $12.7M. The largest seller was Millennium Management, exiting entirely with an estimated $5.97M sold.

  • 258 institutional investors held Pacira BioSciences (PCRX) as of Q3 2026, up from 254 in Q2 2026.
  • Funds reported $1.15B of Pacira BioSciences stock for Q3 2026, up 2.9% quarter-over-quarter.
  • 34 funds opened new Pacira BioSciences positions in Q3 2026 and 25 closed out, a net change of +9 holders.
  • The largest Pacira BioSciences buyer in Q3 2026 was Jacobs Levy Equity Management, an estimated $12.7M added.
  • The largest Pacira BioSciences seller in Q3 2026 was Millennium Management, an estimated $5.97M sold.

Based on aggregated 13F filings for Q3 2026.